Quick Takeaways:
- Rejuvenate Bio has entered a strategic R&D collaboration with Merck Animal Health (MAH) to advance a novel gene therapy program in animal health.
- The partnership will leverage Rejuvenate Bio’s platform technologies and translational expertise to develop targeted gene therapies addressing unmet needs in veterinary medicine, with a focus on chronic and age-related conditions in companion animals.
- Alongside the collaboration, Rejuvenate Bio has raised a $6M financing round led by VCapital, with participation from MAH, Kendall Capital Partners, Connecticut Innovations, and Digitalis. The funding will support continued development of its gene therapy platform and pipeline, including therapies for chronic and age-associated diseases in companion animals.
Why It Matters?
This deal gives Merck Animal Health an early, exclusive window into a gene-therapy pipeline for chronic and age-related diseases in pets, while Rejuvenate Bio secures non-dilutive R&D support and a $6M financing round to advance its platform.
The companion-animal gene-therapy space could see accelerated development in high-value chronic conditions (e.g., cardiomyopathy, kidney disease, arthritis), with Merck positioned to potentially commercialize a differentiated, one-time treatment modality alongside its existing portfolio, creating a new, high-margin category in veterinary medicine.
Source: Businesswire
